Ligand Pharmaceuticals (LGND) FCF Margin (2010 - 2026)
Ligand Pharmaceuticals (LGND) reported FCF Margin of 93.7% for Q1 2026, up 15030.0% on a YoY basis from N/an in Q1 2025, and up 22.33% sequentially from 76.59% in Q4 2025.
Ligand Pharmaceuticals (LGND) FCF Margin (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 17 years of FCF Margin data on file, last reported at 93.7% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 15030.0% year-over-year to 93.7%; the trailing twelve-month figure through Mar 2026 stood at 44.91% (up 1684.0% YoY), and the FY2025 full-year result was 18.33%, down 3864.0% from the prior year.
- FCF Margin rose to 93.7% in Q1 2026, from 76.59% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 129.08% in Q1 2022 to a low of 56.6% in Q1 2025.
- A 5-year average of 46.2% and a median of 39.75% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin plunged 11673 bps in 2025 and surged 15030 bps in 2026, its largest moves.
- Tracing LGND's FCF Margin over 5 years: stood at 77.76% in 2022, then tumbled by 49 bps to 39.75% in 2023, then surged by 63 bps to 64.84% in 2024, then climbed by 18 bps to 76.59% in 2025, then grew by 22 bps to 93.7% in 2026.
- Business Quant data shows LGND's FCF Margin at 93.7% in Q1 2026, 76.59% in Q4 2025, and 11.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | 93.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.70% |
| Dec 31, 2025 | 76.59% |
| Sep 30, 2025 | 11.34% |
| Jun 30, 2025 | 33.60% |
| Mar 31, 2025 | -56.60% |
| Dec 31, 2024 | 64.84% |
| Sep 30, 2024 | 69.35% |
| Jun 30, 2024 | 31.08% |
| Mar 31, 2024 | 60.13% |
| Dec 31, 2023 | 39.75% |
| Sep 30, 2023 | 15.44% |
| Jun 30, 2023 | 6.83% |
| Mar 31, 2023 | 71.70% |
| Dec 31, 2022 | 77.76% |
| Sep 30, 2022 | 34.89% |
| Jun 30, 2022 | 25.84% |
| Mar 31, 2022 | 129.08% |
| Dec 31, 2021 | 47.22% |
| Sep 30, 2021 | 40.64% |
| Jun 30, 2021 | 24.08% |